Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director · CEO and Chairman | August 17, 2026 | August 20, 2026 |
| Cerevel Therapeutics Holdings, Inc.ARYB · Entity 15182 | Director | June 04, 2020 | June 04, 2020 |
| EQRx, Inc.CMLT · Entity 108311 | Director | April 06, 2021 | April 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date August 17, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,180,518 |
Ending reported balance
After 2026-08-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-08-17 · Exercise / conversion · Acquired 321,324 · Balance 2,501,842 Row 2 · 2026-08-17 · Sale · Disposed 318,799 · Balance 2,183,043 F1: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-08-17 · Sale · Disposed 2,525 · Balance 2,180,518 F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 4 · 2026-08-18 · Exercise / conversion · Acquired 278,676 · Balance 2,459,194 Row 5 · 2026-08-18 · Sale · Disposed 278,472 · Balance 2,180,722 F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 6 · 2026-08-18 · Sale · Disposed 204 · Balance 2,180,518 F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 · Expires 2028-02-07 | Direct | 278,676 |
Reported balance
After 2026-08-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-17 · Exercise / conversion · Disposed 321,324 · Balance 278,676 F5: The option was fully vested and exercisable and would have expired on February 7, 2028. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 · Expires 2028-02-07 | Direct | 0 |
Reported balance
After 2026-08-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-18 · Exercise / conversion · Disposed 278,676 · Balance 0 F5: The option was fully vested and exercisable and would have expired on February 7, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5: The option was fully vested and exercisable and would have expired on February 7, 2028.
Cerevel Therapeutics Holdings, Inc.
Report date June 04, 2020 · Filed June 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-238488) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
EQRx, Inc.
Report date April 06, 2021 · Filed April 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-04-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-253475) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-253475) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 278,676 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780649-26-000014 · form4.xml · derivative · entry 8 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 278,676 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was fully vested and exercisable and would have expired on February 7, 2028. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 204 | $25.14 | $5,128.56 |
DisclosureSEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,180,518 F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 278,472 | $24.48 | $6,816,994.56 |
DisclosureSEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,180,722 F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 278,676 | $6.55 | $1,825,327.80 |
DisclosureSEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,459,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 321,324 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780649-26-000014 · form4.xml · derivative · entry 7 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,676 Underlying: Common Stock · 321,324 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was fully vested and exercisable and would have expired on February 7, 2028. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,525 | $25.57 | $64,564.25 |
DisclosureSEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,180,518 F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 318,799 | $25.08 | $7,995,478.92 |
DisclosureSEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,183,043 F1 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 321,324 | $6.55 | $2,104,672.20 |
DisclosureSEC source: 0001780649-26-000014 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,501,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2026 Filed Apr 8, 2026 23:51 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 37,263 | $15.19 | $566,024.97 |
DisclosureSEC source: 0001780649-26-000011 · form4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,180,518 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 23:51 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 83,332 | $14.41 | $1,200,814.12 |
DisclosureSEC source: 0001780649-26-000011 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,217,781 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.19 to $14.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 329,600 | $13.17 | $4,340,832.00 |
DisclosureSEC source: 0001780649-26-000007 · form4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,301,113 F2 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 140,567 | $13.17 | $1,851,267.39 |
DisclosureSEC source: 0001780649-26-000007 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,630,713 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2026 Filed Mar 7, 2026 00:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 709,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001780649-26-000005 · form4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,771,280 F1 · kind: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 6, 2023, with respect to the three-year period ending on March 6, 2026. The issuer certified the achievement of the performance goals on March 6, 2026. The performance share units vested on March 6, 2026. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 127,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001780649-26-000005 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,062,060 Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 00:51 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,380 | $16.15 | $38,437.00 |
DisclosureSEC source: 0001780649-26-000003 · primary_doc.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,934,247 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.11 to $16.23, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 00:51 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 50,703 | $15.49 | $785,389.47 |
DisclosureSEC source: 0001780649-26-000003 · primary_doc.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,936,627 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $16.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 00:51 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 289,024 | $15.82 | $4,572,359.68 |
DisclosureSEC source: 0001780649-26-000003 · primary_doc.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,987,330 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:51 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 182,891 | $15.99 | $2,924,427.09 |
DisclosureSEC source: 0001780649-26-000003 · primary_doc.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,276,354 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.83 to $16.20, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 00:37 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 124,998 | $18.44 | $2,304,963.12 |
DisclosureSEC source: 0001780649-26-000002 · primary_doc.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,459,245 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 01:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 124,998 | $15.59 | $1,948,718.82 |
DisclosureSEC source: 0001780649-26-000001 · primary_doc.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,584,243 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.31 to $15.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 00:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 124,998 | $18.94 | $2,367,462.12 |
DisclosureSEC source: 0001780649-25-000003 · primary_doc.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,709,241 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.78 to $19.20, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 26, 2025 Filed Dec 2, 2025 00:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 35,736 | $19.68 | $703,284.48 |
DisclosureSEC source: 0001780649-25-000003 · primary_doc.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,834,239 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.43 to $20.29, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 00:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,867 | $15.00 | $28,005.00 |
DisclosureSEC source: 0001780649-25-000002 · primary_doc.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,869,975 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.03, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 00:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,237 | $14.57 | $18,023.09 |
DisclosureSEC source: 0001780649-25-000002 · primary_doc.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,871,851 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.52 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 00:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 86,161 | $14.73 | $1,269,151.53 |
DisclosureSEC source: 0001780649-25-000002 · primary_doc.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,873,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.37 to $15.05, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 102,218 | $7.64 | $780,945.52 |
DisclosureSEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,959,249 F3 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 247,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,061,467 F2 · kind: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 4, 2022, with respect to the three-year period ending on March 4, 2025. The issuer certified the achievement of the performance goals on March 5, 2025. The performance share units vested on March 5, 2025. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 36,145 | $6.99 | $252,653.55 |
DisclosureSEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,814,350 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 81,206 | $6.98 | $566,817.88 |
DisclosureSEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,850,495 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 355,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004809 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,931,701 Read SEC document |
| February 20, 2025 Filed Feb 22, 2025 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 99,107 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001062993-25-003241 · form4.xml · derivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,107 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 20, 2025 Filed Feb 22, 2025 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 99,107 | $8.44 | $836,463.08 |
DisclosureSEC source: 0001062993-25-003241 · form4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,576,701 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.69, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 20, 2025 Filed Feb 22, 2025 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 99,107 | $6.32 | $626,356.24 |
DisclosureSEC source: 0001062993-25-003241 · form4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,675,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 186,080 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001062993-25-003241 · form4.xml · derivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,107 Underlying: Common Stock · 186,080 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 186,080 | $8.46 | $1,574,236.80 |
DisclosureSEC source: 0001062993-25-003241 · form4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,576,701 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 186,080 | $6.32 | $1,176,025.60 |
DisclosureSEC source: 0001062993-25-003241 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,762,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 211,160 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · derivative · entry 9 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,187 Underlying: Common Stock · 211,160 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 211,160 | $8.50 | $1,794,860.00 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,576,701 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 211,160 | $6.32 | $1,334,531.20 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,787,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 158,921 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · derivative · entry 8 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 496,347 Underlying: Common Stock · 158,921 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 158,921 | $8.46 | $1,344,471.66 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,576,701 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.69, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 158,921 | $6.32 | $1,004,380.72 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,735,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 100,287 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · derivative · entry 7 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 655,268 Underlying: Common Stock · 100,287 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 100,287 | $8.44 | $846,422.28 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,576,701 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 01:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 100,287 | $6.32 | $633,813.84 |
DisclosureSEC source: 0001062993-25-002744 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,676,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:40 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 42,794 | $3.43 | $146,783.42 |
DisclosureSEC source: 0001062993-24-005758 · form4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,576,701 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:40 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,879 | $3.44 | $20,223.76 |
DisclosureSEC source: 0001062993-24-005758 · form4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,619,495 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:40 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 354,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005758 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625,374 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 354,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006321 · form4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,270,764 Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,815 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-22-017696 · doc4.xml · derivative · entry 10 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,555 Underlying: Common Stock · 14,815 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2021. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.